Journals / SDÜ Tıp Fakültesi Dergisi / 2022 / Cilt: 29 - Sayı: 4

COULD GROWTH DIFFERENTIATION FACTOR-15 BE A NEW INFLAMMATORY PATHWAY IN PSORIASIS VULGARIS?

BÜYÜME FARKLILAŞMA FAKTÖRÜ-15 PSORİASİS VULGARİSTE YENİ BİR İNFLAMATUVAR YOLAK OLABİLİR Mİ?

Pages
603–609
Publication Date
2022-12-27
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Serum GDF-15 and TNF-α levels were found to be significantly higher in the patient group compared to the control group (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective Psoriasis vulgaris is a chronic inflammatory disease, in which T cells play an important role in the etiopathogenesis and inflammatory mechanisms.
📊
Key Findings & Data:Growth differentiation factor (GDF) 15 is a member of the transforming growth factor beta superfamily (TGF-ß), which increases with inflammation and has various cell regulatory functions.
💡
Conclusion & Impact:Serum GDF-15 and TNF-α levels were found to be significantly higher in the patient group compared to the control group (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Psoriasis · inflamasyon · GDF15

Abstract

Objective Psoriasis vulgaris is a chronic inflammatory disease, in which T cells play an important role in the etiopathogenesis and inflammatory mechanisms. Growth differentiation factor (GDF) 15 is a member of the transforming growth factor beta superfamily (TGF-ß), which increases with inflammation and has various cell regulatory functions. In this study; it was aimed to evaluate the relationship between serum GDF-15 level and tumor necrosis factor alpha (TNF-α), which is thought to have a role in the etiopathogenesis of the disease, and other metabolic parameters. Material and Method Forty-one patients with psoriasis vulgaris and 41 healthy controls were included in the study. Dermatological examination of all patients was performed and the psoriasis area severity index (PASI) score was calculated. Height and weight measurements, systolic and diastolic blood pressures, waist and hip circumferences, lipid profiles, and biochemical parameters of the patients were evaluated. Serum GDF-15 and TNF-α levels were measured by the ELISA method. Results There was no significant difference between the patient and control groups in terms of age, gender, lipid profiles, biochemical parameters and high-sensitivity C-reactive protein (hs-CRP) levels. Serum GDF-15 and TNF-α levels were found to be significantly higher in the patient group compared to the control group (p

Özet

Amaç Psoriasis vulgaris kronik inflamatuvar bir hastalık olup, etyopatogenezde T hücrelerin önemli rol oynadığı inflamatuvar mekanizmalar rol almaktadır. Son yıllarda psoriasisin sadece deriye sınırlı olmayıp aynı zamanda bazı komorbiditeler ile ilişkili olduğu gösterilmiştir. Büyüme farklılaşma faktörü-15 (GDF-15), dönüştürücü büyüme faktörü beta süper ailesinin (TGF-ß) bir üyesidir ve inflamasyonla artmaktadır. Bu çalışmada; serum GDF-15 düzeyi ve bunun hastalığın etyopatogenezinde rolü olduğu düşünülen tümör nekrozis faktör alfa (TNF-α) ve diğer metabolik parametrelerle arasındaki ilişkinin değerlendirilmesi amaçlandı. Gereç ve Yöntem Çalışmaya 41 psoriasis vulgarisli hasta ve 41 sağlıklı kontrol dahil edildi. Tüm katılımcıların dermatolojik muayenesi yapıldı ve psoriasis alan ve şiddet indeksi (PAŞİ) skoru hesaplandı. Tüm katılımcıların boy, kilo ölçümleri, sistolik ve diastolik kan basınçları, bel ve kalça çevreleri, lipit profilleri, biyokimyasal parametreleri değerlendirildi. Serum GDF-15 ve TNF-α düzeyleri ELİSA yöntemi ile ölçüldü. Bulgular Hasta ve kontrol grubu arasında yaş, cinsiyet, lipit profilleri, biyokimyasal parametreler ve yüksek-sensitif C-reaktif protein (hs-CRP) düzeyleri açısından anlamlı fark gözlenmedi. Hasta grubunda kontrol grubuna kıyasla serum GDF-15 ve TNF-α düzeyleri anlamlı derecede yüksek bulundu (p

🔖

Cite This Article

KORKMAZ, S., ŞİRİN, F. B., AYVAZ, H. H., ERTURAN, İ., YILDIRIM, M. (2022). COULD GROWTH DIFFERENTIATION FACTOR-15 BE A NEW INFLAMMATORY PATHWAY IN PSORIASIS VULGARIS?. SDÜ Tıp Fakültesi Dergisi, Cilt: 29 - Sayı: 4, 603–609. https://ajindex.com/articles/870558

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Ergun T. Etiopathogenesis of Psoriasis. Turkderm 2008; 42 Suppl 2: 18-22
  2. Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019 23;20(6):1475
  3. Takahashi H, Iızuka H. Psoriasis and metabolic syndrome. Journal of Dermatology 2012;39:212-8
  4. Yalcin MM, Altinova AE, Akturk M, Gulbahar O, Arslan E, Sendoğan DO et al. GDF-15 and Hepcidin Levels in Nonanemic Patients with Impaired Glucose Tolerance. J Diabetes Res. 2016;2016:1240843
  5. Adela R, Banerjee SK. GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective. J Diabetes Res. 2015; 2015: 490842
  6. Akbari H, Talaee R, Zaker ZF, Nikoueinejad H. Investigating the Correlation between Growth Differentiation Factor 15 Serum Level and Its Gene Expression with Psoriasis and Its Severity. Iran J Allergy Asthma Immunol. 2021;20(5):593-599
  7. Gülekon A, Adışen E. Psoriasis and Co-morbidities. Turkderm 2008;42:2:23-5
  8. Ku SH, Kwon WJ, Cho EB, Park EJ, Kim KH, Kim KJ. The Association between Psoriasis Area and Severity Index and Cardiovascular Risk Factor in Korean Psoriasis Patients. Ann Dermatol. 2016; 28: 360-3
  9. Shashaj B, Luciano R, Contoli B, Morino GS, Spreghini MR, Rustico C et al. Reference ranges of HOMA-IR in normal-weight and obese young Caucasians. Acta Diabetol. 2016;53(2):251- 60
  10. Desmedt S, Desmedt V, Leen De Vos LD, Delanghe JR, Reinhart Speeckaert R et al. Growth differentiation factor 15: A novel biomarker with high clinical potential. Crit Rev Clin Lab Sci.2019;56(5):333-350
  11. Ünal B, Alan S, Başsorgun Cİ, Karakaş AA, Elpek GÖ, Çiftçioğlu MA. The divergent roles of growth differentiation factor-15 (GDF-15) in benign and malignant skin pathologies. Arch Dermatol Res. 2015;307(7):551-7
  12. Tanrıkulu O, Sarıyıldız ME, Batmaz İ, Yazmalar L, Polat N, Kaplan İ et al. Serum GDF-15 level in rheumatoid arthritis: relationship with disease activity and subclinical atherosclerosis. Acta Reumatol Port. 2017;42(1):66-72
  13. Taşolar MK, Erfan G, Raimoğlu O, Albayrak H, Yanık ME. Role of GDF-15 as an inflammatory marker in patients with psoriasis vulgaris. Turkderm 2021;55:184-8
  14. Bao X, Borné Y, Muhammad IF, Nilsson J, Lind L,Malender O et al. Growth differentiation factor 15 is positively associated with incidence of diabetes mellitus: the Malmö Diet and Cancer-Cardiovascular Cohort. Diabetologia. 2019;62(1):78-86
  15. Pavo N, Wurm R, Neuhold S, Adlbrecht C, Vila G, Strunk G et al. GDF-15 Is Associated with Cancer